Results 41 to 50 of about 355,709 (346)

Screening and diagnosis of NSCLC

Annals of Oncology, 2004
Lung cancer is the biggest cancer killer in Europe. Non-small-cell lung cancer (NSCLC) accounts for the vast majority ofcases. The annual number of newly diagnosed patients inEurope exceeds 200000, accounting for 20% of all cancerdeaths, and on average 28% of male cancer deaths across thecontinent [1, 2].
Van Meerbeeck, Jan, Tournoy, Kurt
openaire   +4 more sources

Lung Segmentectomy in NSCLC Surgery

Life, 2023
Current guidelines recommend surgery for early-stage non-small cell lung cancer (NSCLC). The standard treatment for patients with cT1N0 NSCLC has been lobectomy with lymph-node dissection, with sublobar resection used only in patients with inadequate cardio-respiratory reserve, with poor performance status, or who are elderly.
Alberto Salvicchi, Simone Tombelli, Giovanni Mugnaini, Alessandro Gonfiotti   +3 more
openaire   +3 more sources

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Cancer Research, Statistics, and Treatment, 2019
Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months.
Akhil Rajendra, Vanita Noronha, Amit Joshi, Vijay Maruti Patil, Nandini Menon, Kumar Prabhash   +5 more
doaj   +1 more source

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival

OncoImmunology, 2021
Immune checkpoint inhibitors (ICIs) have improved the survival of patients with non-small cell lung cancer (NSCLC) by reinvigorating tumor-specific T cell responses.
Fiamma Berner, Rebekka Niederer, Jolien J. Luimstra, Oltin Tiberiu Pop, Ann-Kristin Jochum, Mette-Triin Purde, Omar Hasan Ali, David Bomze, Jens Bauer, Lena Katharina Freudenmann, Ana Marcu, Eva-Maria Wolfschmitt, Sebastian Haen, Thorben Gross, Marissa Lisa Dubbelaar, Marie-Therese Abdou, Petra Baumgaertner, Christina Appenzeller, Caroline Cicin-Sain, Tobias Lenz, Daniel E. Speiser, Burkhard Ludewig, Christoph Driessen, Markus Jörger, Martin Früh, Wolfram Jochum, Antonio Cozzio, Hans-Georg Rammensee, Juliane Walz, Jacques Neefjes, Lukas Flatz   +30 more
doaj   +1 more source

Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review

South Asian Journal of Cancer, 2022
Akhil Kapoor Introduction The prognosis of anaplastic lymphoma kinase (ALK) fusion-positive metastatic non-small cell lung cancer (mNSCLC) patients has improved drastically since the introduction of targeted
Satvik Khaddar, Akhil Kapoor, Vanita Noronha, Vijay M. Patil, Nandini Menon, Abhishek Mahajan, Amit Janu, Rajiv Kumar, Nilendu Purandare, Kumar Prabhash   +9 more
doaj   +1 more source

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation

OncoImmunology, 2021
Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy.
Wei Nie, Lu Gan, Xin Wang, Kai Gu, Fang-Fei Qian, Min-Juan Hu, Ding Zhang, Shi-Qing Chen, Jun Lu, Shu-Hui Cao, Jing-Wen Li, Yue Wang, Bo Zhang, Shu-Yuan Wang, Chang-Hui Li, Ping Yang, Mi–Die Xu, Xue-Yan Zhang, Hua Zhong, Bao-Hui Han   +19 more
doaj   +1 more source

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Drugs in Context, 2022
Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS ...
Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio, Giulio Metro   +10 more
doaj   +1 more source

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis

Open Medicine, 2023
The efficacy of immune checkpoint inhibitors (ICIs) on KRAS-mutant advanced non-small cell lung cancer (NSCLC) remains controversial. This retrospective study compared the effects of ICIs treatment and chemotherapy on the prognosis of patients with KRAS ...
Gu Xiaodong, Si Jinfei, Guan Yelan, Xu Yibing, Shao Lan, Zhang Yiping, Xu Chunwei, Pan Weiwei, Lu Yuanzhi, Song Zhengbo, Wang Wenxian   +10 more
doaj   +1 more source

Ferroptosis inducer erastin sensitizes NSCLC cells to celastrol through activation of the ROS–mitochondrial fission–mitophagy axis

Molecular Oncology, 2021
Despite recent progress in non‐small‐cell lung cancer (NSCLC) treatment, treatment outcomes remain poor, mainly because of treatment resistance or toxicity.
Ming Liu, Yumei Fan, Danyu Li, Bihui Han, Yanxiu Meng, Fei Chen, Tianchan Liu, Zhiyuan Song, Yu-Mi Han, Liying Huang, Yanzhong Chang, P. Cao, A. Nakai, K. Tan   +13 more
semanticscholar   +1 more source

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

Медицинский совет, 2019
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily.
K. K. Laktionov, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov, D. T. Marinov, D. A. Peregudov, M. S. Ardzinba   +7 more
doaj   +1 more source